Trump announces 0% tariff on generic medicines for two years; 200% thereafter
President Trump announced a new tariff policy for imported generic medicines, starting with a two-year duty-free period followed by steep increases up to 200%. The policy aims to force pharmaceutical companies to reshore manufacturing to the United States.
Why it matters
This policy represents a significant shift in healthcare supply chain strategy, potentially impacting drug costs and availability in the US.
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years and then steep tariff hikes aimed at bringing pharmaceutical manufacturing back to the country.Announcing the policy, Trump said the move was intended to encourage companies to manufacture generic medicines domestically."Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter. This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in